EUVIMEDEUVIMED entdecken
Crossref

Fecal microbiota transplantation combined with atezolizumab plus bevacizumab in hepatocellular carcinoma refractory to atezolizumab plus bevacizumab: an open label, single-arm, phase II pilot study (FAB-HCC)

K Pomej, A Frick, B Scheiner, M Baumgartner, K Schmetterer, C S Reyna-Blanco, L Balcar, L Pajancic, A Kreuter, J Seneca Silva, H Bela, T Köcher und 14 weitere

Zeitschrift für Gastroenterologie · 01.05.2026 · 64 (05) · e105

DOI: 10.1055/s-0046-1823014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.05.2026. Verfasst von K Pomej und 25 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Modulation of the gut microbiome (fecal microbiota transplant (FMT)) may help to overcome resistance to immune checkpoint inhibitors. Material and Methods In this single-center, single-arm pilot study (ClinicalTrials.gov ID: NCT05750030), we included patients with advanced HCC who progressed on atezolizumab/bevacizumab. Patients received a single FMT via colonoscopy from an anti-PD-1-responding HCC donor or healthy donor, combined with atezolizumab/bevacizumab q3w. The primary endpoint was safety, measured by incidence and severity of treatment-related adverse events (TRAEs). The main secondary endpoint was best overall response according to mRECIST and RECISTv1.1. For exploratory analyses, blood and stool samples were collected longitudinally. Stool samples were processed for 16S rRNA sequencing. Bile acids were measured with LC-MS/MS in stool and plasma samples. PBMCs were analyzed by flow cytometry. Phage-display immunoprecipitation sequencing was performed on plasma samples to profile systemic IgG-epitope repertoires against gut microbiota and environmental antigens using a phage library comprising 357,000 peptides.

Results

Between August 2023 and November 2024, 12 patients were included (male, n=10; Child-Pugh A, n=11; BCLC C, n=10). Grade 3-4 TRAEs included arterial hypertension (n=5) and proteinuria (n=3), both related to bevacizumab, and diarrhea (n=1), related to FMT. No serious TRAEs were observed. Objective response rate according to mRECIST and RECISTv1.1 was 33% and 25%, respectively. Median progression-free survival was 6.9 (95%CI, 3.0-10.8) months (mRECIST) and 4.3 (95%CI, 0.2-8.5) months (RECISTv1.1). FMT resulted in a significant shift of recipient microbiome towards donor microbiome. Healthy-donor FMT was associated with higher engraftment than anti-PD-1-responder-FMT. We observed changes in gut microbiota composition, fecal and plasma levels of secondary bile acids, and circulating immune cell populations. PhIP-Seq revealed that antibody repertoire stability, rather than global diversity or composition, changed over time, and this finding was more pronounced in responders compared to non-responders.

Conclusion

FMT combined with atezolizumab/bevacizumab was safe and achieved a high response rate in patients with atezolizumab/bevacizumab-refractory HCC. Publication History Article published online: 08 June 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Pomej, K., Frick, A., Scheiner, B., Baumgartner, M., Schmetterer, K., Reyna-Blanco, C. S., Balcar, L., Pajancic, L., Kreuter, A., Silva, J. S., Bela, H., Köcher, T., Prinzensteiner, M., Lampichler, K., Rohr-Udilova, N., Chakrabarty, A., Klotz, A., Lampl, A., Zinober, K., …, & Pinter, M. (2026). Fecal microbiota transplantation combined with atezolizumab plus bevacizumab in hepatocellular carcinoma refractory to atezolizumab plus bevacizumab: an open label, single-arm, phase II pilot study (FAB-HCC). Zeitschrift für Gastroenterologie, 64(05), e105. https://doi.org/10.1055/s-0046-1823014

Vancouver

Pomej K, Frick A, Scheiner B, Baumgartner M, Schmetterer K, Reyna-Blanco CS, et al. Fecal microbiota transplantation combined with atezolizumab plus bevacizumab in hepatocellular carcinoma refractory to atezolizumab plus bevacizumab: an open label, single-arm, phase II pilot study (FAB-HCC). Zeitschrift für Gastroenterologie. 2026;64(05):e105. doi:10.1055/s-0046-1823014

BibTeX
@article{Pomej2026,
  author = {Pomej, K and Frick, A and Scheiner, B and Baumgartner, M and Schmetterer, K and Reyna-Blanco, C S and Balcar, L and Pajancic, L and Kreuter, A and Silva, J Seneca and Bela, H and Köcher, T and Prinzensteiner, M and Lampichler, K and Rohr-Udilova, N and Chakrabarty, A and Klotz, A and Lampl, A and Zinober, K and Regnat, K and Trauner, M and Berry, D and Tamandl, D and Vogl, T and Gasche, C and Pinter, M},
  title = {Fecal microbiota transplantation combined with atezolizumab plus bevacizumab in hepatocellular carcinoma refractory to atezolizumab plus bevacizumab: an open label, single-arm, phase II pilot study (FAB-HCC)},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2026},
  volume = {64},
  number = {05},
  pages = {e105},
  doi = {10.1055/s-0046-1823014}
}
Kostenlos starten →